首页 > 最新文献

Biomedical Papers-Olomouc最新文献

英文 中文
Blood loss in coronary artery bypass grafting on minimally invasive extracorporeal circulation - a single-centre experience and retrospective analysis. 微创体外循环冠状动脉旁路移植术中的失血-单中心经验和回顾性分析。
IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-04-25 DOI: 10.5507/bp.2025.012
Jan Juchelka, Martin Simek, Dominik Sabacky, Marek Vicha, Artur Barshatskyi, Ondrej Zuscich, Martin Troubil, Roman Hajek, Jana Zapletalova, Petr Santavy

Background: Minimally-invasive extracorporeal circulation (MiECC) is confirmed to mitigate the post-perfusion syndrome resulting in better outcomes in operated patients compared to the conventional cardiopulmonary bypass (ECC).

Aims: To determine whether there is a clinical benefit of lower blood loss in patients operated on MiECC compared to ECC. To provide a detailed construction of modified MiECC and its perfusion management.

Methods: Retrospective analysis of the clinical data of 60 patients undergoing coronary artery bypass grafting on MiECC or ECC. The primary outcome was to compare the following variables in the 2 groups: intraoperative and 30-day mortality and cardiovascular death, myocardial infarction and cerebral stroke (MACCE). Secondary outcomes included surgical revision for bleeding or tamponade, intraoperative and postoperative blood loss and the consumption of packed red blood cell units. We modified our MiECC by connecting a cardiotomy suction.

Results: There was no mortality, major adverse events or surgical revisions in either group. No difference was found for intraoperative blood loss. The MiECC group had significantly lower overall postoperative blood loss (660 mL vs 765 mL, P=0.037). Total consumption of packed red blood cell units was insignificantly higher in the ECC group (n=30 vs n=20, P=0.490).

Conclusion: MiECC is a safe alternative to conventional ECC in routine procedures such as CABG. Its improved biocompatibility was reflected by better preservation of hemostasis in this study.

背景:微创体外循环(MiECC)被证实可以减轻灌注后综合征,与传统的体外循环(ECC)相比,手术患者的预后更好。目的:确定与ECC相比,MiECC手术患者的出血量更低是否有临床益处。目的:对改良后的MiECC进行详细的构建和灌注管理。方法:回顾性分析60例采用MiECC或ECC行冠状动脉旁路移植术的临床资料。主要结局是比较两组的以下变量:术中和30天死亡率以及心血管死亡、心肌梗死和脑卒中(MACCE)。次要结果包括出血或填塞的手术翻修,术中和术后失血以及填充红细胞单位的消耗。我们通过连接开心术抽吸器改良了MiECC。结果:两组患者均无死亡、重大不良事件或手术翻修。术中出血量无差异。MiECC组术后总出血量显著降低(660 mL vs 765 mL, P=0.037)。填充红细胞单位的总消耗在ECC组中无统计学意义(n=30 vs n=20, P=0.490)。结论:在CABG等常规手术中,MiECC是一种安全的替代方法。其改善的生物相容性反映在本研究中更好的止血保存。
{"title":"Blood loss in coronary artery bypass grafting on minimally invasive extracorporeal circulation - a single-centre experience and retrospective analysis.","authors":"Jan Juchelka, Martin Simek, Dominik Sabacky, Marek Vicha, Artur Barshatskyi, Ondrej Zuscich, Martin Troubil, Roman Hajek, Jana Zapletalova, Petr Santavy","doi":"10.5507/bp.2025.012","DOIUrl":"https://doi.org/10.5507/bp.2025.012","url":null,"abstract":"<p><strong>Background: </strong>Minimally-invasive extracorporeal circulation (MiECC) is confirmed to mitigate the post-perfusion syndrome resulting in better outcomes in operated patients compared to the conventional cardiopulmonary bypass (ECC).</p><p><strong>Aims: </strong>To determine whether there is a clinical benefit of lower blood loss in patients operated on MiECC compared to ECC. To provide a detailed construction of modified MiECC and its perfusion management.</p><p><strong>Methods: </strong>Retrospective analysis of the clinical data of 60 patients undergoing coronary artery bypass grafting on MiECC or ECC. The primary outcome was to compare the following variables in the 2 groups: intraoperative and 30-day mortality and cardiovascular death, myocardial infarction and cerebral stroke (MACCE). Secondary outcomes included surgical revision for bleeding or tamponade, intraoperative and postoperative blood loss and the consumption of packed red blood cell units. We modified our MiECC by connecting a cardiotomy suction.</p><p><strong>Results: </strong>There was no mortality, major adverse events or surgical revisions in either group. No difference was found for intraoperative blood loss. The MiECC group had significantly lower overall postoperative blood loss (660 mL vs 765 mL, P=0.037). Total consumption of packed red blood cell units was insignificantly higher in the ECC group (n=30 vs n=20, P=0.490).</p><p><strong>Conclusion: </strong>MiECC is a safe alternative to conventional ECC in routine procedures such as CABG. Its improved biocompatibility was reflected by better preservation of hemostasis in this study.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticoagulation in device-detected atrial fibrillation: Challenges in stroke prevention and heart failure management. 设备检测心房颤动的抗凝:卒中预防和心力衰竭管理的挑战。
IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-04-14 DOI: 10.5507/bp.2025.010
Jiri Vrtal, Jiri Plasek, Jan Vaclavik, Jozef Dodulik, David Sipula

Atrial fibrillation (AF), the most common cardiac arrhythmia globally, contributes significantly to morbidity and mortality. With advancements in implantable devices like pacemakers, defibrillators, and loop recorders, incidental detection of AF as device-detected AF (DDAF) or subclinical AF (SCAF) has become common. This asymptomatic AF presents unique management challenges, particularly in anticoagulation decisions for stroke prevention. Evidence from recent trials, notably NOAH-AFNET 6 and ARTESiA, indicates a complex risk-benefit profile for anticoagulation in DDAF. In ARTESiA, anticoagulation modestly reduced stroke and systemic embolism rates, though this effect did not reach statistical significance. The NOAH-AFNET 6 trial found no significant reduction in a composite of cardiovascular death, stroke, or systemic embolism with anticoagulation compared to placebo. Both trials revealed an increased bleeding risk, underscoring the need to carefully weigh stroke prevention against bleeding risks in DDAF. The 2024 European Society of Cardiology guidelines reflect this nuanced approach by advocating a tailored, risk-based strategy. Emerging evidence also shows that AF burden impacts heart failure (HF) outcomes, with a five-fold increase in HF hospitalizations associated with higher AF burden. This highlights the importance of rhythm or rate control to reduce HF progression, particularly in patients with both AF and HF, where reducing AF burden is associated with better prognosis and fewer hospitalizations. Future research should focus on refining anticoagulation strategies, especially for patients with low AF burden, and exploring novel approaches like intermittent anticoagulation and advanced monitoring to support personalized DDAF management.

房颤(AF)是全球最常见的心律失常,对发病率和死亡率有重要影响。随着起搏器、除颤器和循环记录仪等植入式设备的进步,偶然检测到AF为设备检测AF (DDAF)或亚临床AF (SCAF)已经变得很常见。这种无症状房颤提出了独特的管理挑战,特别是在卒中预防的抗凝决策中。最近的试验,特别是NOAH-AFNET 6和ARTESiA的证据表明,DDAF抗凝治疗具有复杂的风险-收益特征。在ARTESiA中,抗凝适度降低了卒中和全身栓塞率,尽管这种效果没有达到统计学意义。NOAH-AFNET 6试验发现,与安慰剂相比,抗凝治疗没有显著降低心血管死亡、中风或全身性栓塞的复合发生率。两项试验均显示出血风险增加,强调在DDAF中需要仔细权衡卒中预防和出血风险。2024年欧洲心脏病学会指南通过倡导量身定制的、基于风险的策略,反映了这种微妙的方法。新出现的证据还表明,房颤负担影响心力衰竭(HF)的结局,房颤负担加重导致HF住院率增加5倍。这突出了心律或心率控制对减少心衰进展的重要性,特别是在房颤和心衰患者中,减少房颤负担与更好的预后和更少的住院治疗有关。未来的研究应侧重于完善抗凝策略,特别是对于房颤负担低的患者,并探索间歇性抗凝和高级监测等新方法,以支持个性化的DDAF管理。
{"title":"Anticoagulation in device-detected atrial fibrillation: Challenges in stroke prevention and heart failure management.","authors":"Jiri Vrtal, Jiri Plasek, Jan Vaclavik, Jozef Dodulik, David Sipula","doi":"10.5507/bp.2025.010","DOIUrl":"https://doi.org/10.5507/bp.2025.010","url":null,"abstract":"<p><p>Atrial fibrillation (AF), the most common cardiac arrhythmia globally, contributes significantly to morbidity and mortality. With advancements in implantable devices like pacemakers, defibrillators, and loop recorders, incidental detection of AF as device-detected AF (DDAF) or subclinical AF (SCAF) has become common. This asymptomatic AF presents unique management challenges, particularly in anticoagulation decisions for stroke prevention. Evidence from recent trials, notably NOAH-AFNET 6 and ARTESiA, indicates a complex risk-benefit profile for anticoagulation in DDAF. In ARTESiA, anticoagulation modestly reduced stroke and systemic embolism rates, though this effect did not reach statistical significance. The NOAH-AFNET 6 trial found no significant reduction in a composite of cardiovascular death, stroke, or systemic embolism with anticoagulation compared to placebo. Both trials revealed an increased bleeding risk, underscoring the need to carefully weigh stroke prevention against bleeding risks in DDAF. The 2024 European Society of Cardiology guidelines reflect this nuanced approach by advocating a tailored, risk-based strategy. Emerging evidence also shows that AF burden impacts heart failure (HF) outcomes, with a five-fold increase in HF hospitalizations associated with higher AF burden. This highlights the importance of rhythm or rate control to reduce HF progression, particularly in patients with both AF and HF, where reducing AF burden is associated with better prognosis and fewer hospitalizations. Future research should focus on refining anticoagulation strategies, especially for patients with low AF burden, and exploring novel approaches like intermittent anticoagulation and advanced monitoring to support personalized DDAF management.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of Vibrio parahaemolyticus sensitive and specific loop-mediated isothermal amplification combined with lateral flow device. 副溶血性弧菌敏感特异性环介导等温扩增结合侧流装置的研制。
IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-06 DOI: 10.5507/bp.2025.007
Xiaoheng Liang, Dan Zhan, Xin Huang, Jinli Bi, Jinghan Li, Liqin Meng, Li Xie, Taijie Li

Background and aim: Vibrio parahaemolyticus a gram-negative, rod-shaped bacterium with salinophilic properties is found mainly in rivers, oceans, and coastal environments. With the expanding scale of aquaculture in coastal regions of China, the contamination of seafoods with Vibrio parahaemolyticus is becoming a significant cause of food poisoning with symptoms including gastroenteritis, wound infection and sepsis. Current methods for detecting this microorganism are unsuitable in the present context. We developed a rapid LAMP-LFD method-by combining the loop-mediated isothermal amplification technique (LAMP) and lateral flow device (LFD).

Methods: The thermolabile hemolysin tlh gene of Vibrio parahaemolyticus was used as the target, and we designed five specific primers in its conserved region. The primers were used to carry LAMP reaction with biotin labelling, the products completed hybridisation with the FAM-labelled primers, and the hybridisation products were tested for results on LFD.

Results: The results showed that the LAMP-LFD method specifically detected Vibrio parahaemolyticus and was negative for proximate strains such as Vibrio vulnificus and other Vibrio pathogens as well as common pathogens such as Escherichia coli. The optimised reaction conditions for LAMP were 40 min at 60 °C, plus 5 min of probe hybridisation and 3-5 min of LFD color development. The lowest concentration of Vibrio parahaemolyticus pure culture bacterial fluid of 1.5×102 cfu/mL could be detected, and the pathogen could be detected from tissue samples with a contamination concentration of 0.75×103 cfu/mL. The method has higher specificity and sensitivity, and the pathogen can be detected within 1.5 h.

Conclusion: The LAMP-LFD method for Vibrio parahaemolyticus established in this study has the advantages of convenient operation, low dependence on equipment, high sensitivity and rapid detection, all of make it ideally suited to the detection of Vibrio parahaemolyticus at the grass-roots level.

背景和目的:副溶血性弧菌是一种革兰氏阴性的棒状细菌,具有嗜盐性,主要存在于河流、海洋和沿海环境中。随着中国沿海地区水产养殖规模的不断扩大,副溶血性弧菌污染海产品正成为引起胃肠炎、伤口感染、败血症等食物中毒的重要原因。目前检测这种微生物的方法不适合目前的情况。我们将环介导等温扩增技术(LAMP)与侧流装置(LFD)相结合,建立了一种快速LAMP-LFD方法。方法:以副溶血性弧菌的耐热溶血素tlh基因为靶点,在其保守区设计5条特异性引物。引物进行LAMP反应,标记生物素,与标记fam的引物杂交,在LFD上检测杂交结果。结果:LAMP-LFD方法对副溶血性弧菌有特异性检测,对创伤弧菌等病原菌和大肠埃希菌等常见病原菌的检测均为阴性。LAMP的优化反应条件为:60℃下40 min,探针杂交5 min, LFD显色3-5 min。可检出最低浓度为1.5×102 cfu/mL的副溶血性弧菌纯培养菌液,污染浓度为0.75×103 cfu/mL的组织样品可检出病原菌。结论:本研究建立的LAMP-LFD副溶血性弧菌检测方法操作方便,对设备依赖性低,灵敏度高,检测速度快,非常适合基层副溶血性弧菌的检测。
{"title":"Development of Vibrio parahaemolyticus sensitive and specific loop-mediated isothermal amplification combined with lateral flow device.","authors":"Xiaoheng Liang, Dan Zhan, Xin Huang, Jinli Bi, Jinghan Li, Liqin Meng, Li Xie, Taijie Li","doi":"10.5507/bp.2025.007","DOIUrl":"https://doi.org/10.5507/bp.2025.007","url":null,"abstract":"<p><strong>Background and aim: </strong>Vibrio parahaemolyticus a gram-negative, rod-shaped bacterium with salinophilic properties is found mainly in rivers, oceans, and coastal environments. With the expanding scale of aquaculture in coastal regions of China, the contamination of seafoods with Vibrio parahaemolyticus is becoming a significant cause of food poisoning with symptoms including gastroenteritis, wound infection and sepsis. Current methods for detecting this microorganism are unsuitable in the present context. We developed a rapid LAMP-LFD method-by combining the loop-mediated isothermal amplification technique (LAMP) and lateral flow device (LFD).</p><p><strong>Methods: </strong>The thermolabile hemolysin tlh gene of Vibrio parahaemolyticus was used as the target, and we designed five specific primers in its conserved region. The primers were used to carry LAMP reaction with biotin labelling, the products completed hybridisation with the FAM-labelled primers, and the hybridisation products were tested for results on LFD.</p><p><strong>Results: </strong>The results showed that the LAMP-LFD method specifically detected Vibrio parahaemolyticus and was negative for proximate strains such as Vibrio vulnificus and other Vibrio pathogens as well as common pathogens such as Escherichia coli. The optimised reaction conditions for LAMP were 40 min at 60 °C, plus 5 min of probe hybridisation and 3-5 min of LFD color development. The lowest concentration of Vibrio parahaemolyticus pure culture bacterial fluid of 1.5×10<sup>2</sup> cfu/mL could be detected, and the pathogen could be detected from tissue samples with a contamination concentration of 0.75×10<sup>3</sup> cfu/mL. The method has higher specificity and sensitivity, and the pathogen can be detected within 1.5 h.</p><p><strong>Conclusion: </strong>The LAMP-LFD method for Vibrio parahaemolyticus established in this study has the advantages of convenient operation, low dependence on equipment, high sensitivity and rapid detection, all of make it ideally suited to the detection of Vibrio parahaemolyticus at the grass-roots level.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum drug levels and medication adherence in heart failure: A comparative cohort analysis. 心力衰竭患者血清药物水平和药物依从性:一项比较队列分析。
IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-06 DOI: 10.5507/bp.2025.006
Libor Jelinek, Martin Modrak, Jan Vaclavik, Zdenek Ramik, Lukas Stos, Marie Lazarova, Radek Adamek, Hana Janeckova, Jana Spurna

Objective: To determine changes in medication adherence in two cohorts of heart failure patients differing by year of data collection and using a direct method of adherence detection - serum drug level testing.

Methods: We added a second cohort of patients to a prospective monocentric registry of chronic heart failure patients (LEVEL-CHF registry). The two cohorts share the same inclusion criteria but differ by the year of enrolment (2018 and 2020). Stable patients with heart failure with reduced ejection fraction were enrolled in a specialized university hospital center.

Results: We included 402 records of 366 individual patients, 274 in 2018 and 128 in 2020. 36 patients were enrolled in both cohorts. Of the total 81% of patients were fully adherent, and 19% were non-adherent to a varying degree. Between 2018 and 2020 there was a statistically significant increase in BMI (P=0.047) and fasting glycemia (P=0.009). Patients in the 2020 cohort were less adherent than those in the 2018 cohort (P<0.01). Patients in the two cohorts had similarly severe heart failure and did not substantially differ in NYHA class. There were no statistically significant differences between adherent and non-adherent patients after adjusting for multiple comparisons.

Conclusions: In this comparison, most patients were fully adherent to all their medication and very few were non-adherent to multiple medications. We found no clinically relevant differences between adherent and non-adherent patients. Serum drug level testing is an effective method of adherence testing in clinical practice.

目的:采用直接的药物依从性检测方法-血清药物水平检测,确定两组心力衰竭患者药物依从性的变化,这些患者的数据收集年份不同。方法:我们在慢性心力衰竭患者的前瞻性单中心登记(LEVEL-CHF登记)中加入了第二组患者。这两个队列具有相同的纳入标准,但不同的入组年份(2018年和2020年)不同。稳定的心力衰竭伴射血分数降低的患者被登记在一个专门的大学医院中心。结果:我们纳入了366例个体患者的402例记录,2018年为274例,2020年为128例。两个队列均纳入了36例患者。81%的患者完全坚持治疗,19%的患者不同程度地不坚持治疗。在2018年至2020年期间,BMI (P=0.047)和空腹血糖(P=0.009)有统计学意义的增加。2020年队列患者的依从性低于2018年队列患者(p结论:在本比较中,大多数患者完全坚持所有药物治疗,极少数患者不坚持多种药物治疗。我们没有发现粘附和非粘附患者之间的临床相关差异。血清药物水平检测是临床应用中一种有效的药物依从性检测方法。
{"title":"Serum drug levels and medication adherence in heart failure: A comparative cohort analysis.","authors":"Libor Jelinek, Martin Modrak, Jan Vaclavik, Zdenek Ramik, Lukas Stos, Marie Lazarova, Radek Adamek, Hana Janeckova, Jana Spurna","doi":"10.5507/bp.2025.006","DOIUrl":"https://doi.org/10.5507/bp.2025.006","url":null,"abstract":"<p><strong>Objective: </strong>To determine changes in medication adherence in two cohorts of heart failure patients differing by year of data collection and using a direct method of adherence detection - serum drug level testing.</p><p><strong>Methods: </strong>We added a second cohort of patients to a prospective monocentric registry of chronic heart failure patients (LEVEL-CHF registry). The two cohorts share the same inclusion criteria but differ by the year of enrolment (2018 and 2020). Stable patients with heart failure with reduced ejection fraction were enrolled in a specialized university hospital center.</p><p><strong>Results: </strong>We included 402 records of 366 individual patients, 274 in 2018 and 128 in 2020. 36 patients were enrolled in both cohorts. Of the total 81% of patients were fully adherent, and 19% were non-adherent to a varying degree. Between 2018 and 2020 there was a statistically significant increase in BMI (P=0.047) and fasting glycemia (P=0.009). Patients in the 2020 cohort were less adherent than those in the 2018 cohort (P<0.01). Patients in the two cohorts had similarly severe heart failure and did not substantially differ in NYHA class. There were no statistically significant differences between adherent and non-adherent patients after adjusting for multiple comparisons.</p><p><strong>Conclusions: </strong>In this comparison, most patients were fully adherent to all their medication and very few were non-adherent to multiple medications. We found no clinically relevant differences between adherent and non-adherent patients. Serum drug level testing is an effective method of adherence testing in clinical practice.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and molecular genetic analysis of cytologically uncertain thyroid nodules in patients with thyroid disease. 甲状腺疾病患者细胞学不确定甲状腺结节的临床和分子遗传学分析。
IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 Epub Date: 2023-12-06 DOI: 10.5507/bp.2023.048
Jindrich Lukas, Barbora Hintnausova, Vlasta Sykorova, Martin Syrucek, Marek Maly, David Lukas, Jaroslava Duskova

Background: The current requirement is to establish the preoperative diagnosis accurately as possible and to achieve an adequate extent of surgery. The aim of this study was to define the preoperative clinical and molecular genetic risks of malignancy in indeterminate thyroid nodules (Bethesda III and IV) and to determine their impact on the surgical strategy.

Methods: Prospectively retrospective analysis of 287 patients provided the basis of preoperative laboratory examination, sonographic stratification of malignancy risks and cytological findings. Molecular tests focused on pathogenic variants of genes associated with thyroid oncogenesis in cytologically indeterminate nodules (Bethesda III and IV). The evaluation included clinical risk factors: positive family history, radiation exposure and growth in size and/or number of nodules.

Results: Preoperative FNAB detected 52 cytologically indeterminate nodules (28.7%) out of 181 patients. Postoperative histopathological examination revealed malignancy in 12 cases (23.7%) and there was no significant difference between Bethesda III and IV categories (P=0.517). Clinical risk factors for malignancy were found in 32 patients (61.5%) and the presence of at least one of them resulted in a clearly higher incidence of malignancy than their absence (31.3% vs. 10.0%, respectively). Pathogenic variants of genes were detected in 12/49 patients in Bethesda III and IV, and in 4 cases (33.3%) thyroid carcinoma was revealed. The rate of malignancies was substantially higher in patients with pathogenic variants than in those without (33.3% vs. 16.2%, respectively).

Conclusions: Our experience implies that molecular genetic testing is one of several decision factors. We will continue to monitor and enlarge our patient cohort to obtain long-term follow-up data.

背景:目前的要求是尽可能准确地建立术前诊断,并达到充分的手术程度。本研究的目的是确定不确定甲状腺结节(Bethesda III和IV)术前恶性肿瘤的临床和分子遗传学风险,并确定其对手术策略的影响。方法:对287例患者进行前瞻性回顾性分析,为术前实验室检查、恶性危险超声分层及细胞学检查结果提供依据。分子检测侧重于细胞学上不确定结节(Bethesda III和IV)中与甲状腺癌发生相关的基因致病性变异。评估包括临床危险因素:阳性家族史、辐射暴露和结节大小和/或数量的增长。结果:181例患者术前FNAB检出52例细胞学不确定结节(28.7%)。术后组织病理学检查显示恶性肿瘤12例(23.7%),Bethesda III型与IV型差异无统计学意义(P=0.517)。32例(61.5%)患者发现了恶性肿瘤的临床危险因素,其中至少一项的存在导致恶性肿瘤的发生率明显高于不存在的患者(分别为31.3%和10.0%)。Bethesda III和IV期患者中有12/49例检测到致病性基因变异,4例(33.3%)显示甲状腺癌。有致病变异的患者的恶性肿瘤发生率明显高于无致病变异的患者(分别为33.3%和16.2%)。结论:我们的经验表明,分子基因检测是几个决定因素之一。我们将继续监测并扩大患者队列以获得长期随访数据。
{"title":"Clinical and molecular genetic analysis of cytologically uncertain thyroid nodules in patients with thyroid disease.","authors":"Jindrich Lukas, Barbora Hintnausova, Vlasta Sykorova, Martin Syrucek, Marek Maly, David Lukas, Jaroslava Duskova","doi":"10.5507/bp.2023.048","DOIUrl":"10.5507/bp.2023.048","url":null,"abstract":"<p><strong>Background: </strong>The current requirement is to establish the preoperative diagnosis accurately as possible and to achieve an adequate extent of surgery. The aim of this study was to define the preoperative clinical and molecular genetic risks of malignancy in indeterminate thyroid nodules (Bethesda III and IV) and to determine their impact on the surgical strategy.</p><p><strong>Methods: </strong>Prospectively retrospective analysis of 287 patients provided the basis of preoperative laboratory examination, sonographic stratification of malignancy risks and cytological findings. Molecular tests focused on pathogenic variants of genes associated with thyroid oncogenesis in cytologically indeterminate nodules (Bethesda III and IV). The evaluation included clinical risk factors: positive family history, radiation exposure and growth in size and/or number of nodules.</p><p><strong>Results: </strong>Preoperative FNAB detected 52 cytologically indeterminate nodules (28.7%) out of 181 patients. Postoperative histopathological examination revealed malignancy in 12 cases (23.7%) and there was no significant difference between Bethesda III and IV categories (P=0.517). Clinical risk factors for malignancy were found in 32 patients (61.5%) and the presence of at least one of them resulted in a clearly higher incidence of malignancy than their absence (31.3% vs. 10.0%, respectively). Pathogenic variants of genes were detected in 12/49 patients in Bethesda III and IV, and in 4 cases (33.3%) thyroid carcinoma was revealed. The rate of malignancies was substantially higher in patients with pathogenic variants than in those without (33.3% vs. 16.2%, respectively).</p><p><strong>Conclusions: </strong>Our experience implies that molecular genetic testing is one of several decision factors. We will continue to monitor and enlarge our patient cohort to obtain long-term follow-up data.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":"26-31"},"PeriodicalIF":0.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138500311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Results of surgical therapy of functioning pituitary adenomas. 功能性垂体腺瘤的手术治疗结果。
IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 Epub Date: 2023-09-21 DOI: 10.5507/bp.2023.037
Vlastimil Novak, Lumir Hrabalek, Jan Schovanek, Zdenek Frysak, Racheal Temitope Ijisesan Perryova, Daniel Pohlodek

Introduction: Functioning pituitary adenomas lead to substantial morbidity and increased mortality associated with typical endocrine syndromes. Surgical therapy is an integral part of the management of these tumours. The aim of this study was to evaluate the results of surgical transnasal procedures in patients with functioning pituitary adenomas who underwent the surgery at the Department of Neurosurgery, University Hospital Olomouc.

Methods: Patients with functioning pituitary adenoma (ACTH, GH, PRL) were indicated for surgery. All patients underwent preoperative and postoperative endocrinological examination and laboratory tests to assess excessive or deficient hormonal production and imaging examination.

Results: The cohort consisted of 58 patients, 33 of whom were women and 25 men. The age range was 12-77 years (mean age 47.6 years). Microadenoma was diagnosed in 58.6% of patients and macroadenoma in 41.4% of patients. The most common hypersecretory syndrome was excessive production of growth hormone (56.9%), followed by excessive production of adrenocorticotropic hormone (24.1%) and prolactin (12.1%). In the group with excessive production of ACTH, complete remission was achieved after the first surgery in 78.6% of cases (72.8% for microadenomas (8) and 100% (3) cases in macroadenomas); in the group with excessive GH production in 51.4% (63.2% (7) in microadenomas and 46.2% (12) cases in macroadenomas). In the group with excessive production of PRL, it was 57.1% (100% (2) in microadenomas and 40% (2) cases in macroadenomas).

Conclusion: Surgical therapy in the presented cohort led to the normalisation of hormonal excessive production in 58.6% of cases. A combination of drug therapy and radiotherapeutic methods was necessary in the remaining cases to achieve hormonal remission.

引言:功能性垂体腺瘤会导致与典型内分泌综合征相关的大量发病率和死亡率增加。手术治疗是这些肿瘤管理的一个组成部分。本研究的目的是评估在奥洛穆克大学医院神经外科接受手术的功能性垂体腺瘤患者的经鼻手术结果。方法:选择功能性垂体瘤(ACTH、GH、PRL)患者进行手术。所有患者均接受了术前和术后内分泌检查和实验室检查,以评估激素分泌过多或不足以及影像学检查。结果:该队列包括58名患者,其中33人为女性,25人为男性。年龄范围为12-77岁(平均47.6岁)。58.6%的患者诊断出微腺瘤,41.4%的患者诊断为大腺瘤。最常见的高分泌综合征是生长激素分泌过多(56.9%),其次是促肾上腺皮质激素(24.1%)和泌乳素(12.1%)。在ACTH分泌过多的组中,78.6%的病例在第一次手术后完全缓解(微腺瘤72.8%(8),大腺瘤100%(3));生长激素分泌过多组为51.4%(微腺瘤为63.2%(7),大腺瘤为46.2%(12))。在PRL过量产生的组中,其为57.1%(微腺瘤为100%(2),大腺瘤为40%(2))。在剩下的病例中,药物治疗和放射治疗方法的结合是必要的,以实现激素缓解。
{"title":"Results of surgical therapy of functioning pituitary adenomas.","authors":"Vlastimil Novak, Lumir Hrabalek, Jan Schovanek, Zdenek Frysak, Racheal Temitope Ijisesan Perryova, Daniel Pohlodek","doi":"10.5507/bp.2023.037","DOIUrl":"10.5507/bp.2023.037","url":null,"abstract":"<p><strong>Introduction: </strong>Functioning pituitary adenomas lead to substantial morbidity and increased mortality associated with typical endocrine syndromes. Surgical therapy is an integral part of the management of these tumours. The aim of this study was to evaluate the results of surgical transnasal procedures in patients with functioning pituitary adenomas who underwent the surgery at the Department of Neurosurgery, University Hospital Olomouc.</p><p><strong>Methods: </strong>Patients with functioning pituitary adenoma (ACTH, GH, PRL) were indicated for surgery. All patients underwent preoperative and postoperative endocrinological examination and laboratory tests to assess excessive or deficient hormonal production and imaging examination.</p><p><strong>Results: </strong>The cohort consisted of 58 patients, 33 of whom were women and 25 men. The age range was 12-77 years (mean age 47.6 years). Microadenoma was diagnosed in 58.6% of patients and macroadenoma in 41.4% of patients. The most common hypersecretory syndrome was excessive production of growth hormone (56.9%), followed by excessive production of adrenocorticotropic hormone (24.1%) and prolactin (12.1%). In the group with excessive production of ACTH, complete remission was achieved after the first surgery in 78.6% of cases (72.8% for microadenomas (8) and 100% (3) cases in macroadenomas); in the group with excessive GH production in 51.4% (63.2% (7) in microadenomas and 46.2% (12) cases in macroadenomas). In the group with excessive production of PRL, it was 57.1% (100% (2) in microadenomas and 40% (2) cases in macroadenomas).</p><p><strong>Conclusion: </strong>Surgical therapy in the presented cohort led to the normalisation of hormonal excessive production in 58.6% of cases. A combination of drug therapy and radiotherapeutic methods was necessary in the remaining cases to achieve hormonal remission.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":"32-36"},"PeriodicalIF":0.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous transthoracic needle biopsy of lung lesions is a safe method associated with a very low risk of pleural recurrence. 经皮经胸针活检肺部病变是一种安全的方法,胸膜复发的风险非常低。
IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 Epub Date: 2024-09-27 DOI: 10.5507/bp.2024.030
Martin Svaton, David Havel, Marcela Buresova, Jan Baxa, Petr Hosek

Aim: Percutaneous transthoracic needle biopsy (PTNB), an alternative to bronchoscopic confirmation of lung lesions, is today being associated with a risk of pneumothorax and hemorrhage. Further, there are no data on the possible risk of malignant disease spreading to the pleura at the site of the PTNB. Previous studies have dealt with this risk in stage I non-small cell lung cancer only. The aim of this study was thus to assess the risk of pleural recurrence for all types of lung lesions. Secondary objectives included assessment of diagnostic yield and safety with respect to the incidence of pneumothorax and hemorrhage.

Methods: Clinical data of all patients from the University Hospital in Pilsen who had undergone PTNB of lung lesions between 1.1.2018 and 31.12.2022 were included in this retrospective study.

Results: Following PTNB, ipsilateral pleural effusion occurred in 4.8% of patients without prior pleural infiltration. The effusion was confirmed as malignant in one patient (0.7%). Diagnostic yield of the method was 86.6%. We recorded pneumothorax or hemorrhage in the lung parenchyma or pleural space requiring medical intervention in 3.4% and 1.1% of patients, respectively.

Conclusion: In our study, percutaneous transthoracic needle biopsy of lung lesions showed high sensitivity and low degree of acute complications requiring an invasive solution. The risk of pleural recurrence after a biopsy was very low. Consequently, we continue to consider this method to be an alternative to bronchoscopy biopsies.

目的:经皮经胸穿刺活检术(PTNB)是支气管镜确认肺部病变的一种替代方法,但目前存在气胸和出血的风险。此外,目前还没有数据显示恶性疾病在PTNB部位扩散到胸膜的可能风险。以往的研究只涉及 I 期非小细胞肺癌的这种风险。因此,本研究旨在评估所有类型肺部病变的胸膜复发风险。次要目标包括评估诊断率以及气胸和出血发生率方面的安全性:这项回顾性研究纳入了比尔森大学医院在2018年1月1日至2022年12月31日期间接受肺部病变PTNB治疗的所有患者的临床数据:4.8%的患者在PTNB术后出现同侧胸腔积液,且之前未出现胸膜浸润。一名患者(0.7%)的积液被确诊为恶性。该方法的诊断率为 86.6%。我们分别记录了3.4%和1.1%的患者出现气胸或肺实质或胸膜腔出血,需要进行医疗干预:在我们的研究中,经皮经胸针活检肺部病变显示出较高的灵敏度和较低的急性并发症发生率。活检后胸膜复发的风险非常低。因此,我们仍然认为这种方法可以替代支气管镜活检。
{"title":"Percutaneous transthoracic needle biopsy of lung lesions is a safe method associated with a very low risk of pleural recurrence.","authors":"Martin Svaton, David Havel, Marcela Buresova, Jan Baxa, Petr Hosek","doi":"10.5507/bp.2024.030","DOIUrl":"10.5507/bp.2024.030","url":null,"abstract":"<p><strong>Aim: </strong>Percutaneous transthoracic needle biopsy (PTNB), an alternative to bronchoscopic confirmation of lung lesions, is today being associated with a risk of pneumothorax and hemorrhage. Further, there are no data on the possible risk of malignant disease spreading to the pleura at the site of the PTNB. Previous studies have dealt with this risk in stage I non-small cell lung cancer only. The aim of this study was thus to assess the risk of pleural recurrence for all types of lung lesions. Secondary objectives included assessment of diagnostic yield and safety with respect to the incidence of pneumothorax and hemorrhage.</p><p><strong>Methods: </strong>Clinical data of all patients from the University Hospital in Pilsen who had undergone PTNB of lung lesions between 1.1.2018 and 31.12.2022 were included in this retrospective study.</p><p><strong>Results: </strong>Following PTNB, ipsilateral pleural effusion occurred in 4.8% of patients without prior pleural infiltration. The effusion was confirmed as malignant in one patient (0.7%). Diagnostic yield of the method was 86.6%. We recorded pneumothorax or hemorrhage in the lung parenchyma or pleural space requiring medical intervention in 3.4% and 1.1% of patients, respectively.</p><p><strong>Conclusion: </strong>In our study, percutaneous transthoracic needle biopsy of lung lesions showed high sensitivity and low degree of acute complications requiring an invasive solution. The risk of pleural recurrence after a biopsy was very low. Consequently, we continue to consider this method to be an alternative to bronchoscopy biopsies.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":"21-25"},"PeriodicalIF":0.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142332863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study protocol - Prospective case-control trial - Impact of significant carotid stenosis on retinal perfusion measured with automated retinal oximetry. 研究方案 - 前瞻性病例对照试验 - 颈动脉明显狭窄对自动视网膜血氧仪测量的视网膜灌注的影响。
IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 Epub Date: 2024-01-03 DOI: 10.5507/bp.2023.052
Petr Polidar, Barbora Paskova, Marta Karhanova, Martin Sin, Tomas Dornak, Zuzana Schreiberova, Petra Divisova, Tomas Veverka, David Franc, Daniel Sanak, Michal Kral

Background: Large vessel carotid stenosis is a significant cause of ischaemic stroke. Indications for surgical revascularisation depend on the severity of the stenosis and clinical symptoms. However, mild symptoms such as TIA (Transient ischaemic attack), amaurosis fugax or minor stroke precede large strokes in only 15% of cases.

Aim: The aim of this prospective study is to evaluate whether retinal perfusion is impacted in significant carotid stenosis. Automated retinal oximetry will be used to better assess perfusion in the post-stenotic basin. We presume the more stenotic the blood vessel, the more reduced the retinal perfusion is, resulting in adaptive changes such as greater arteriovenous saturation difference due to greater oxygen extraction. This could broaden the indication spectrum for revascularisation for carotid stenosis.

Methods: We plan to enroll yearly 50 patients with significant carotid stenosis and cross-examine them with retinal oximetry. The study group will provide stenotic vessels and, non-stenotic vessels will form the control group. Patients with significant carotid stenosis will undergo an MRI (Magnetic Resonnance imaging) examination to determine the presence of asymptomatic recent ischaemic lesions in the stenotic basin, and the correlation to oximetry parameters.

Statistics: The stenosis severity and retinal oximetry parameters will be compared for study and control groups with a threshold of 70%, respectively 80% and 90% stenosis. Results will be then reevaluated with emphasis on MRI findings in the carotid basin.

Conclusion: This prospective case control study protocol will be used to launch a multicentre trial assessing the relationship between significant carotid stenosis and retinal perfusion measured with automated retinal oximetry. Despite these differences, the findings indicate the potential of retinal oximetry for noninvasive real-time measurements of oxyhaemoglobin saturation in central nervous system vessels. Following calibration upgrade and technological improvement, verification retinal oximetry may potentially be applied to critically ill and anaesthesia care patients. The study on combined scanning laser ophthalmoscope and retinal oximetry supports the feasibility of the technique for oximetry analysis in newly born babies.

Trial registration: ClinicalTrials.gov, ID: NCT06085612.

背景:颈动脉大血管狭窄是缺血性中风的重要原因。手术血管重建的指征取决于狭窄的严重程度和临床症状。目的:这项前瞻性研究旨在评估严重颈动脉狭窄是否会影响视网膜灌注。将使用自动视网膜血氧仪更好地评估狭窄后盆地的灌注情况。我们推测,血管狭窄程度越大,视网膜灌注就越少,从而导致适应性变化,如由于氧气萃取量增大而导致动静脉饱和度差异增大。这可能会扩大颈动脉狭窄血管再通的适应症范围:我们计划每年招募 50 名颈动脉明显狭窄的患者,用视网膜血氧仪对他们进行交叉检查。研究组将提供狭窄血管,非狭窄血管将作为对照组。颈动脉明显狭窄的患者将接受核磁共振成像(MRI)检查,以确定狭窄盆地是否存在无症状的近期缺血性病变,以及与血氧饱和度参数的相关性:统计:将比较研究组和对照组的狭窄严重程度和视网膜血氧饱和度参数,阈值分别为 70%、80% 和 90%。结论:这项前瞻性病例对照研究方案将对颈动脉狭窄的严重程度和视网膜血氧饱和度参数进行比较,研究组和对照组的阈值分别为 70%、80% 和 90%:这项前瞻性病例对照研究方案将用于启动一项多中心试验,评估颈动脉明显狭窄与自动视网膜血氧仪测量的视网膜灌注之间的关系。尽管存在这些差异,但研究结果表明,视网膜血氧仪具有无创实时测量中枢神经系统血管中氧合血红蛋白饱和度的潜力。在校准升级和技术改进之后,验证性视网膜血氧仪有可能应用于重症患者和麻醉护理患者。对扫描激光眼底镜和视网膜血氧仪的联合研究证明了该技术用于新生儿血氧分析的可行性:试验注册:ClinicalTrials.gov,ID:试验注册:ClinicalTrials.gov,ID:NCT06085612。
{"title":"Study protocol - Prospective case-control trial - Impact of significant carotid stenosis on retinal perfusion measured with automated retinal oximetry.","authors":"Petr Polidar, Barbora Paskova, Marta Karhanova, Martin Sin, Tomas Dornak, Zuzana Schreiberova, Petra Divisova, Tomas Veverka, David Franc, Daniel Sanak, Michal Kral","doi":"10.5507/bp.2023.052","DOIUrl":"10.5507/bp.2023.052","url":null,"abstract":"<p><strong>Background: </strong>Large vessel carotid stenosis is a significant cause of ischaemic stroke. Indications for surgical revascularisation depend on the severity of the stenosis and clinical symptoms. However, mild symptoms such as TIA (Transient ischaemic attack), amaurosis fugax or minor stroke precede large strokes in only 15% of cases.</p><p><strong>Aim: </strong>The aim of this prospective study is to evaluate whether retinal perfusion is impacted in significant carotid stenosis. Automated retinal oximetry will be used to better assess perfusion in the post-stenotic basin. We presume the more stenotic the blood vessel, the more reduced the retinal perfusion is, resulting in adaptive changes such as greater arteriovenous saturation difference due to greater oxygen extraction. This could broaden the indication spectrum for revascularisation for carotid stenosis.</p><p><strong>Methods: </strong>We plan to enroll yearly 50 patients with significant carotid stenosis and cross-examine them with retinal oximetry. The study group will provide stenotic vessels and, non-stenotic vessels will form the control group. Patients with significant carotid stenosis will undergo an MRI (Magnetic Resonnance imaging) examination to determine the presence of asymptomatic recent ischaemic lesions in the stenotic basin, and the correlation to oximetry parameters.</p><p><strong>Statistics: </strong>The stenosis severity and retinal oximetry parameters will be compared for study and control groups with a threshold of 70%, respectively 80% and 90% stenosis. Results will be then reevaluated with emphasis on MRI findings in the carotid basin.</p><p><strong>Conclusion: </strong>This prospective case control study protocol will be used to launch a multicentre trial assessing the relationship between significant carotid stenosis and retinal perfusion measured with automated retinal oximetry. Despite these differences, the findings indicate the potential of retinal oximetry for noninvasive real-time measurements of oxyhaemoglobin saturation in central nervous system vessels. Following calibration upgrade and technological improvement, verification retinal oximetry may potentially be applied to critically ill and anaesthesia care patients. The study on combined scanning laser ophthalmoscope and retinal oximetry supports the feasibility of the technique for oximetry analysis in newly born babies.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, ID: NCT06085612.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":"66-71"},"PeriodicalIF":0.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Number and dynamics of micronuclei and near-tetraploidy predict prognosis in childhood acute leukaemia. 微核和近四倍体的数量和动态预测儿童急性白血病的预后。
IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 Epub Date: 2023-11-22 DOI: 10.5507/bp.2023.046
Sopiko Jashiashvili, Alla Zedginidze, Giorgi Ormotsadze, Asmat Shengelaia

Objectives: This study aims to identify factors possibly contributing to complications in children with acute leukaemia. Despite diverse etiological causes, similar processes trigger the process of cell malignancy. Genomic instability has received considerable attention in this context.

Method: We conducted chromosomal analysis of bone marrow cells and measured the micronuclei (Mn) level in buccal cells over time. Statistical reliability assessment was performed using Analysis of variance (ANOVA), and the data were analyzed and visualized using the SPSS 12 statistical analysis software package.

Results: On the 15th day of treatment, our findings confirmed a statistically significant correlation (χ2=3.88, P=0.04) between the number of blasts in the bone marrow and unfavourable outcome in patients with a near-tetraploid chromosome clone. Additionally, on the 33rd day of treatment, we observed a correlation between an elevated number of Mn and relapses.

Discussion: While it is commonly believed that a hyperdiploid clone with >50 chromosomes in childhood acute lymphoblastic leukaemia confers favorable outcome, our study revealed partially heterogeneous results and poor prognosis in patients with a near-tetraploid clone. We have also identified a correlation between the Mn level on the 33rd day of treatment and the development of complications. It is possible that the increased Mn values and the occurrence of relapses were influenced by the individual patient's sensitivity to the genotoxic effect of the medication.

目的:本研究旨在确定可能导致急性白血病患儿并发症的因素。尽管不同的病因,相似的过程触发细胞恶性肿瘤的过程。基因组不稳定性在这方面受到了相当大的关注。方法:对骨髓细胞进行染色体分析,并随时间测定颊细胞微核(Mn)水平。采用方差分析(ANOVA)进行统计信度评估,使用SPSS 12统计分析软件包对数据进行分析和可视化。结果:在治疗第15天,我们的研究结果证实了骨髓中原细胞数量与近四倍体染色体克隆患者的不良预后之间的统计学显著相关(χ2=3.88, P=0.04)。此外,在治疗的第33天,我们观察到Mn数量升高与复发之间的相关性。讨论:虽然人们普遍认为,儿童急性淋巴细胞白血病患者具有>50条染色体的超二倍体克隆具有良好的预后,但我们的研究显示,近四倍体克隆患者的结果部分不均匀,预后较差。我们还确定了治疗第33天Mn水平与并发症发生之间的相关性。可能升高的Mn值和复发的发生受到个体患者对药物遗传毒性作用的敏感性的影响。
{"title":"Number and dynamics of micronuclei and near-tetraploidy predict prognosis in childhood acute leukaemia.","authors":"Sopiko Jashiashvili, Alla Zedginidze, Giorgi Ormotsadze, Asmat Shengelaia","doi":"10.5507/bp.2023.046","DOIUrl":"10.5507/bp.2023.046","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to identify factors possibly contributing to complications in children with acute leukaemia. Despite diverse etiological causes, similar processes trigger the process of cell malignancy. Genomic instability has received considerable attention in this context.</p><p><strong>Method: </strong>We conducted chromosomal analysis of bone marrow cells and measured the micronuclei (Mn) level in buccal cells over time. Statistical reliability assessment was performed using Analysis of variance (ANOVA), and the data were analyzed and visualized using the SPSS 12 statistical analysis software package.</p><p><strong>Results: </strong>On the 15th day of treatment, our findings confirmed a statistically significant correlation (χ<sup>2</sup>=3.88, P=0.04) between the number of blasts in the bone marrow and unfavourable outcome in patients with a near-tetraploid chromosome clone. Additionally, on the 33rd day of treatment, we observed a correlation between an elevated number of Mn and relapses.</p><p><strong>Discussion: </strong>While it is commonly believed that a hyperdiploid clone with >50 chromosomes in childhood acute lymphoblastic leukaemia confers favorable outcome, our study revealed partially heterogeneous results and poor prognosis in patients with a near-tetraploid clone. We have also identified a correlation between the Mn level on the 33rd day of treatment and the development of complications. It is possible that the increased Mn values and the occurrence of relapses were influenced by the individual patient's sensitivity to the genotoxic effect of the medication.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":"44-48"},"PeriodicalIF":0.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138300701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers. 庆大霉素肾毒性导致的急性肾损伤和作为生物标志物的特异性 miRNA。
IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 Epub Date: 2024-10-11 DOI: 10.5507/bp.2024.031
Viktor Klementa, Nadezda Petejova, Pavel Horak, Ester Kurasova, Josef Zadrazil

Acute kidney injury (AKI) due to gentamicin nephrotoxicity is a significant concern in clinical medicine, particularly in patients receiving prolonged or high-dose gentamicin therapy. Gentamicin is an aminoglycoside antibiotic frequently used in the treatment of a range of bacterial infections. However, its use is associated with nephrotoxicity which can manifest as AKI. Due to this, it is crucial to diagnose promptly and manage treatment effectively. Ongoing studies are therefore focusing on non-protein-coding RNAs as potential biomarkers for AKI. Numerous microRNAs (miRNAs) have been implicated in gentamicin-induced nephrotoxicity and AKI. They participate in pathways associated with inflammation, cell death, and oxidative stress and each of these factors play critical roles in the development of gentamicin-induced kidney injury. Research studies have demonstrated changes in the expression levels of these miRNAs in response to gentamicin exposure both in vitro and in in vivo models, as well as in human clinical trials involving patients receiving gentamicin therapy. The dysregulation of these miRNAs correlates with the severity of kidney injury and may serve as sensitive biomarkers for early detection and monitoring of AKI induced by gentamicin.

庆大霉素肾毒性导致的急性肾损伤(AKI)是临床医学中的一个重要问题,尤其是在接受长期或大剂量庆大霉素治疗的患者中。庆大霉素是一种氨基糖苷类抗生素,常用于治疗各种细菌感染。然而,它的使用与肾毒性有关,肾毒性可表现为 AKI。因此,及时诊断和有效治疗至关重要。因此,正在进行的研究将非蛋白编码 RNA 作为潜在的 AKI 生物标志物。许多微小 RNA(miRNA)都与庆大霉素诱导的肾毒性和 AKI 有关。它们参与了与炎症、细胞死亡和氧化应激相关的通路,而这些因素在庆大霉素诱导的肾损伤的发展过程中都起着至关重要的作用。研究表明,这些 miRNA 在体外和体内模型以及接受庆大霉素治疗的人体临床试验中的表达水平会随着庆大霉素暴露而发生变化。这些 miRNA 的失调与肾损伤的严重程度相关,可作为早期检测和监测庆大霉素诱导的 AKI 的灵敏生物标志物。
{"title":"Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers.","authors":"Viktor Klementa, Nadezda Petejova, Pavel Horak, Ester Kurasova, Josef Zadrazil","doi":"10.5507/bp.2024.031","DOIUrl":"10.5507/bp.2024.031","url":null,"abstract":"<p><p>Acute kidney injury (AKI) due to gentamicin nephrotoxicity is a significant concern in clinical medicine, particularly in patients receiving prolonged or high-dose gentamicin therapy. Gentamicin is an aminoglycoside antibiotic frequently used in the treatment of a range of bacterial infections. However, its use is associated with nephrotoxicity which can manifest as AKI. Due to this, it is crucial to diagnose promptly and manage treatment effectively. Ongoing studies are therefore focusing on non-protein-coding RNAs as potential biomarkers for AKI. Numerous microRNAs (miRNAs) have been implicated in gentamicin-induced nephrotoxicity and AKI. They participate in pathways associated with inflammation, cell death, and oxidative stress and each of these factors play critical roles in the development of gentamicin-induced kidney injury. Research studies have demonstrated changes in the expression levels of these miRNAs in response to gentamicin exposure both in vitro and in in vivo models, as well as in human clinical trials involving patients receiving gentamicin therapy. The dysregulation of these miRNAs correlates with the severity of kidney injury and may serve as sensitive biomarkers for early detection and monitoring of AKI induced by gentamicin.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":"1-8"},"PeriodicalIF":0.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Biomedical Papers-Olomouc
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1